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factorAbstract Background: Airway and vascular remodeling may play a prominent role in the clinical
severity of severe refractory asthma (SRA). Angiopoietin-1 (Ang-1) is an essential mediator of angi-
ogenesis by establishing vascular integrity, whereas angiopoietin-2 (Ang-2) acts as its natural inhib-
itor. Vascular endothelial growth factor (VEGF) is considered to be the most important
angiogenetic factor, which induces vascular endothelial cell proliferation, tubule formation and
increases microvascular permeability.
Objective: In the present study, we aimed to determine the serum levels of angiopoietin-2 and
VEGF in patients with SRA as both are involved in remodeling and angiogenesis occurring in
SRA leading to resistance to inhaled steroid.
Methods: Twenty ﬁve patients with SRA, 25 patients with moderate asthma, and 20 healthy sub-
jects are included in this study. Serum Angiopoietin-2 and vascular endothelial growth factor were
estimated in all groups.
Results: Ang-2 (pg/ml) levels were signiﬁcantly higher among patients with SRA compared to
patients with moderate asthma and healthy control. Vascular endothelial growth factor was signif-
icantly higher in patients with SRA compared with the other two groups.
Conclusion: Results provide suggestion for possible mechanisms involving angiopoietin-2 and
VEGF in the pathogenesis of SRA.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.Introduction
Severe refractory asthma (SRA) is a heterogeneous disorder
that is characterized by persistent asthma symptoms despite
treatment with high-dose inhaled steroids (ICS) [1]. Increased
angiogenesis has been observed in SRA [2], and along with
752 M. Hantera et al.other components of tissue repair and airway inﬂammation,
they may account for the poor steroid response in SRA [3].
Angiogenesis is a complex multiphase process, potentially
involving a great number of growth factors, cytokines, chemo-
kines, and numerous other mediators but the speciﬁc role of
each molecule has not been clearly deﬁned [4]. Vascular endo-
thelial growth factor (VEGF) is considered to be the most
important angiogenetic factor [5,6], which induces vascular
endothelial cell proliferation, tubule formation and increases
microvascular permeability [7]. The latter is a common feature
of vascular remodeling in asthma and is modulated by the
release of different inﬂammatory mediators, cytokines, prote-
ases, and growth factors [4,8].
Angiopoietins 1 and 2 (Ang-1, Ang-2) are both ligands for
the endothelial cell-speciﬁc Tie-2 surface receptor and may act
in a complimentary and coordinated manner along with
VEGF in airway microvascular process. Ang-1 is known to
promote sprouting and stabilizing of nascent vessels by pro-
moting interactions between endothelial cells and surrounding
support cells including pericytes [9]. In contrast, Ang-2 acts as
a natural antagonist of Ang-1 that competes for Tie-2 receptor
and reduces vascular integrity, leading subsequently to
increased vascular permeability and mucosal edema [10]. Data
derived from an animal study suggest that Ang-1 protects
against air way inﬂammation and hyperreactivity in asthma
[11]. Ang-2 is increased in sputum supernatants of steroid-
naive patients with asthma, is related to increased levels of vas-
cular permeability (AVP) index [12]. Recent studies have
shown that Ang-2 levels are elevated in several pathological
conditions [13–15]. Parikh et al. [13] reported that Ang-2 levels
were signiﬁcantly elevated in patients with sepsis and impaired
oxygenation. In addition, serum from these patients induces
disruption of the endothelial barrier, and it has been suggested
that systemic excess of Ang-2 provoked pulmonary leakage
and congestion in healthy adult mice [13].
In the present study, we aimed to determine the serum lev-
els of angiopoietin-2 and VEGF in patients with SRA as both
are involved in remodeling and angiogenesis occurring in SRA
leading to resistance to inhaled steroid.
Patients and methods
Patients
Patients were recruited from outpatient clinics of Cairo and
Tanta chest departments from January 2013 to January
2014. All patients and control are included after taking their
written consent. The diagnosis of asthma was established
according to GINA guidelines [16]. The diagnosis of SRA
was established according to the American Thoracic Society
(ATS) criteria [1]. Fifty patients were included and divided into
25 patients with SRA and 25 patients with moderate asthma,
diagnosed according to the classiﬁcation of GINA 2008 [16].
All patients with asthma were never smokers. Twenty healthy,
nonatopic, nonsmoking subjects served as controls. Patients
with any other respiratory disease or any concomitant malig-
nant, heart, renal, liver or collagen disease as well as subjects
with a respiratory tract infection are excluded from this study.Laboratory investigations including
Solid Phase Sandwich ELISA technique used for the measure-
ment of angiopoietin-2 and vascular endothelial growth factor
(VEGF) levels in serum as a monoclonal antibody speciﬁc for
the measured marker has been precoated onto a microplate.
Standards and samples are pipetted into the wells and the spe-
ciﬁc marker present is bound by the immobilized antibody.
After washing away any unbound substances, an enzyme-
linked monoclonal antibody speciﬁc for the measured marker
is added to the wells. Following a wash to remove any
unbound antibody-enzyme reagent, a substrate solution is
added to the wells and color develops in proportion to the
amount of the measured marker bound in the initial step.
The color development is stopped and the intensity of the color
is measured.
 Estimation of Angiopoietin-2 level in serum using R&D
system Human Angiopoietin-2 Quantikine Pharm Pak
(catalog no. PDANG20). The Quantikine Human
Angiopoietin-2 Immunoassay is a 4.5 hour solid-phase
ELISA designed to measure Human Angiopoietin-2 in
serum. Serum Angiopoietin-2 levels were obtained using
the standard curves of the Quantikine kit standards.
 Estimation of serum level of VEGF using R&D system
Human VEGF Quantikine Pharm Pak (catalog no.
PDVE00). The Quantikine Human VEGF Immunoas-
say is a 4.5 hour solid phase ELISA designed to measure
serum VEGF. Results were obtained from the standard
curves using the Quantikine Human VEGF Immunoas-
say standards.
Lung function
Forced expiratory volume in one-second (FEV1), forced vital
capacity (FVC), FEV1/FVC ratio, and reversibility were mea-
sured using the vitalograph machine according to the ATS
guidelines [17].
Results
Demographic characteristics
Demographic characteristics of the study participants are sum-
marized in Table 1.
Serum level of angiopoietin 2 and vascular endothelial growth
factor
Table 2 shows that Ang-2 (pg/ml) levels differed signiﬁcantly
among patients with SRA, compared to patients with moder-
ate asthma and healthy control. Vascular endothelial growth
factor was signiﬁcantly higher in patients with SRA compared
with the other two groups. Table 2 and Fig. 1 show that in
patients with SRA, Ang-2 is positively correlated with VEGF
(Table 3).
Table 1 Demographic characteristics of study participants.
Variables SRA
(n= 25)
Moderate
asthma (n= 25)
Controls
(n= 20)
P-value
SRA & Moderate SRA & Control Moderate & Control
Age 31.3 ± 11.6 30.6 ± 12.4 32.6 ± 10.5 0.635 0.541 0.717
Sex (female/male) 16/9 14/11 12/8 0.658 0.587 0.752
FEV1% pred. 63 ± 5.36 69 ± 8.21 91 ± 9.36 0.142 0.001
* 0.001*
FVC% pred. 86.2 ± 5.3 93.1 ± 6.5 102 ± 9.6 0.004* 0.002* 0.005*
* Highly signiﬁcant.
Table 2 Serum level of angiopioten-2 and vascular endothelial growth factor in different groups.
Variables SRA
(n= 25)
Moderate
asthma (n= 25)
Controls
(n= 20)
P-value
SRA & Moderate SRA & Control Moderate & Control
Ang-2 (pg/ml) 3650.5 ± 542.7 2200.10 ± 980.9 1865.5 ± 475.3 0.002* 0.001* 0.003*
VEGF (pg/ml) 1020 ± 113.5 445 ± 35.4 201 ± 15.96 0.001* 0.001* 0.001*
* Highly signiﬁcant.
Figure 1 Correlation of Ang-2 and VEGF in severe refractory
asthma.
Table 3 Correlation of Ang-2 and VEGF in severe refractory
asthma.
SRA Ang-2 (pg/ml)
r P
VEGF (pg/ml) 0.639 0.001*
* Highly signiﬁcant.
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In the present study, we have shown that both Ang-2 and
VEGF levels are signiﬁcantly higher in patients with SRA
compared to patients with moderate asthma and healthy
subjects.
Angiopoietins may play a role in vascular remodeling of
asthmatic airways. In particular, Ang-2 levels can be transcrip-
tionally and post-transcriptionally regulated by hypoxia or
exposure to growth factors, such as VEGF [18]. In this study,
both Ang-2 and VEGF were increased in SRA, with a signiﬁ-
cant positive correlation between the two mediators. There-
fore, the high levels of VEGF and Ang-2 observed in ourpatients with SRA may indicate that blood vessels in their air-
ways are in a hypervascularized and destabilized state, thus
contributing to the up-regulation of the AVP process. The
absence of such correlation in moderate asthma suggests a
possible absence of adequate levels of either VEGF and/or
Ang-2 to exert their aforementioned effects.
In the same direction of our study but in sputum superna-
tant E. Tsseliou and colleagues found that angiopoietins are
higher among severe asthmatics and angiopiotine-2 is
associated with mediators involved in both inﬂammatory and
vascular process [19]. Another study showed the correlation
between angiopiotin-2 level and eosinophils explanting the
weak steroid effect in severe asthma [20].
Inhaled steroids are currently the only treatment that may
positively affect the main aspects of the vascular component
of airway inﬂammation and remodeling [7,21]. It is important
to point out that this effect seems to be mainly mediated by the
reduced expression of VEGF [22]. Our study was not designed
to evaluate the possible role of steroid intervention in SRA.
However, the fact that our patients with SRA were receiving
high doses of ICS implies that steroid treatment cannot sup-
press all the aspects of airway inﬂammation and remodeling
in such patients or even more that the underlying pathophysi-
ology of neo-angiogenesis in SRA may be resistant to the
intervention with ICS.
In conclusion, this study indicates that Ang-2 and VEGF
levels are higher in SRA compared with moderate asthma
and healthy subjects. In patients with SRA, Ang-2 is positively
correlated with VEGF which plays a role in vascular
permeability. Our results provide suggestions for possible
mechanisms involving angiopoietin-2 and VEGF in the
pathogenesis of SRA.
This study is only a step in investigating whether angioge-
netic factors play a role in the pathophysiology of SRA.
Further studies are required to deﬁnitively ascertain the role
of Ang-2 and VEGF in SRA.
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